Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zim LaboratoriesNSE:ZIMLAB +1.99%79 EV-to-EBITDA is 17.72 as of Jul. 15, 2026, which is 126% above its 10-year median of 7.84. GuruFocus rates NSE:ZIMLAB with a GF Score™ of 79/100 and a GF Value™ of ₹101.97 (Modestly Overvalued). The stock has 8 warning signs investors should review. Among 740 Drug Manufacturers companies, Zim Laboratories ranks worse than 62.84% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Zim Laboratories's enterprise value is ₹7,334 Mil.
Zim Laboratories's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was ₹414 Mil. Therefore, Zim Laboratories's EV-to-EBITDA for today is 17.72.
The historical rank and industry rank for Zim Laboratories's EV-to-EBITDA or its related term are showing as below:
NSE:ZIMLAB'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 3.06 Med: 7.84 Max: 17.72
Current: 17.72
During the past 12 years, the highest EV-to-EBITDA of Zim Laboratories was 17.72. The lowest was 3.06. And the median was 7.84.
NSE:ZIMLAB's EV-to-EBITDA is ranked worse than 62.84% of 740
companies
in the Drug Manufacturers industry
Industry Median: 13.025
vs NSE:ZIMLAB: 17.72
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Zim Laboratories's PE Ratio (TTM) for today is calculated as:
Zim Laboratories's share price for today is ₹118.20.
Zim Laboratories's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹1.190.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Zim Laboratories's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Zim Laboratories's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zim Laboratories EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Zim Laboratories's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Zim Laboratories's EV-to-EBITDA falls into.
Zim Laboratories's current Enterprise Value is ₹7,334 Mil.
Zim Laboratories's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹414 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zim Laboratories (NSE:ZIMLAB) has a EV-to-EBITDA of 17.72 as of Jul. 15, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Zim Laboratories. This is 126% above median its historical median of 7.84. Over the past decade, Zim Laboratories' EV-to-EBITDA has ranged from 3.06 to 17.72. According to the industry distribution chart, Zim Laboratories ranks #465 out of 740 companies in the Drug Manufacturers industry, placing it in the top 62.8%.
Is Zim Laboratories' EV-to-EBITDA too high?
Zim Laboratories' current EV-to-EBITDA of 17.72 is 126% above median its 10-year median of 7.84. Over the past 10 years, this metric has ranged from a low of 3.06 to a high of 17.72. The Drug Manufacturers industry median EV-to-EBITDA is 13.03. Zim Laboratories' value of 17.72 is 36% above this industry median. Based on the distribution chart, Zim Laboratories ranks #465 out of 740 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Zim Laboratories has a GF Score™ of 79/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Zim Laboratories' EV-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Zim Laboratories ranks #465 out of 740 companies for EV-to-EBITDA. This places Zim Laboratories in the lower half of its industry. The industry median EV-to-EBITDA is 13.03. Zim Laboratories' value of 17.72 is 36% above this benchmark. Historically, Zim Laboratories' own EV-to-EBITDA has ranged from 3.06 to 17.72 over the past decade. While the company's 10-year median is 7.84 vs. the industry median of 13.03, Zim Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.03, based on 740 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zim Laboratories's current EV-to-EBITDA of 17.72 is 36% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Zim Laboratories. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zim Laboratories's current EV-to-EBITDA is 17.72, which is 126% above median its own 10-year median of 7.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zim Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Zim Laboratories (NSE:ZIMLAB) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹101.97, compared to a current price of ₹118.20 — trading 15.9% above its estimated fair value. The current EV-to-EBITDA is 17.72, which is 126% above median its 10-year median of 7.84 and 36% above the Drug Manufacturers industry median of 13.03. Zim Laboratories' overall GF Score™ is 79/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Zim Laboratories (NSE:ZIMLAB), the current EV-to-EBITDA is 17.72 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zim Laboratories (NSE:ZIMLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Zim Laboratories stock appears to be overvalued.
The current stock price of ₹118.20 is trading 15.9% above its estimated GF Value™ of ₹101.97.
GuruFocus considers Zim Laboratories to be Modestly Overvalued.
Key valuation signals for NSE:ZIMLAB:
EV-to-EBITDA: 17.72 (126% above median its 10-year median of 7.84)
GF Value™: ₹101.97 vs. price of ₹118.20 (15.9% above fair value)
Industry Position: 36% above the Drug Manufacturers median (#465 of 740)
No single metric tells the full story. See the NSE:ZIMLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zim Laboratories Ltd is engaged in the manufacturing of formulation drugs and pre formulation ingredients in India and marketing and selling these within and outside India. It is engaged in manufacturing &wholesale of pharmaceutical products, market research and research & development activities. The Group is mainly engaged in the business of pharmaceuticals. It has presence in India and Outside India. The company generates majority of revenue from India. Its products are Oral Thin Films, Pre-formulations Intermediates, Finished Formulations.
79GF Score
Get the complete analysis for NSE:ZIMLAB
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ZIMLAB has been successfully added to your 
